Myozyme (Alglucosidase Alfa)

Alglucosidase alfa, the active ingredient in Myozyme, is an enzyme replacement therapy presented as a 5 mg/mL (100 mg per vial) lyophilized powder for solution for injection for intravenous use. It replaces the deficient acid alpha‑glucosidase enzyme, enabling treatment of Pompe disease in infants, children, and adults.

GNH USA supplies Myozyme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, specialty clinics, and pharmacies across multiple regions worldwide, ensuring reliable access to this EU‑approved therapy, and meeting stringent quality standards.

Myozyme is used in the management of lysosomal storage disorders, specifically Pompe disease.

Infant‑onset Pompe disease: provides enzyme replacement that improves survival rates, supports cardiac function, and enhances motor development in affected infants. Late‑onset Pompe disease in children: helps maintain respiratory capacity, preserve muscle strength, and reduce the frequency of clinical deterioration. Late‑onset Pompe disease in adults: supports slowing of disease progression, stabilizes functional capacity, and may improve endurance and quality of life. Enzyme deficiency correction: restores acid alpha‑glucosidase activity in lysosomes, reducing glycogen accumulation throughout affected tissues.

The most frequently reported adverse reactions to Myozyme are related to the infusion process, while rare but serious events have also been documented.

Common Side Effects: - Infusion‑related reactions (fever, chills, flushing) - Headache - Nausea - Vomiting - Fatigue

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Cardiac arrhythmias or hypotension - Pulmonary edema - Hepatic enzyme elevation

When using Myozyme, several precautions should be observed to minimize risks and ensure optimal therapeutic benefit.

Renal function: monitor serum creatinine and urine output because of potential renal involvement. Cardiac status: assess baseline cardiac function, especially in infant‑onset patients with cardiomyopathy. Infusion rate: initiate at a slow rate and titrate upward to reduce infusion‑related reactions. Immunogenicity: observe for antibody formation that may diminish efficacy or cause hypersensitivity. Pregnancy and lactation: category B; use only if the potential benefit justifies the potential risk. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Myozyme may interact with other medicines, influencing safety or efficacy.

Major Interactions (Avoid): - Concurrent use of other enzyme replacement therapies: may increase immunogenic response. - Live attenuated vaccines: risk of altered immune response; avoid during treatment.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of infusion reactions; monitor patient closely. - Corticosteroids: can affect immune response and potentially modify antibody development. - Beta‑blockers: may blunt heart rate changes during infusion; observe cardiovascular parameters.